Back to Search Start Over

Targeting macrophages with multifunctional nanoparticles to detect and prevent atherosclerotic cardiovascular disease.

Authors :
Nankivell V
Vidanapathirana AK
Hoogendoorn A
Tan JTM
Verjans J
Psaltis PJ
Hutchinson MR
Gibson BC
Lu Y
Goldys E
Zheng G
Bursill CA
Source :
Cardiovascular research [Cardiovasc Res] 2024 Jul 02; Vol. 120 (8), pp. 819-838.
Publication Year :
2024

Abstract

Despite the emergence of novel diagnostic, pharmacological, interventional, and prevention strategies, atherosclerotic cardiovascular disease remains a significant cause of morbidity and mortality. Nanoparticle (NP)-based platforms encompass diverse imaging, delivery, and pharmacological properties that provide novel opportunities for refining diagnostic and therapeutic interventions for atherosclerosis at the cellular and molecular levels. Macrophages play a critical role in atherosclerosis and therefore represent an important disease-related diagnostic and therapeutic target, especially given their inherent ability for passive and active NP uptake. In this review, we discuss an array of inorganic, carbon-based, and lipid-based NPs that provide magnetic, radiographic, and fluorescent imaging capabilities for a range of highly promising research and clinical applications in atherosclerosis. We discuss the design of NPs that target a range of macrophage-related functions such as lipoprotein oxidation, cholesterol efflux, vascular inflammation, and defective efferocytosis. We also provide examples of NP systems that were developed for other pathologies such as cancer and highlight their potential for repurposing in cardiovascular disease. Finally, we discuss the current state of play and the future of theranostic NPs. Whilst this is not without its challenges, the array of multifunctional capabilities that are possible in NP design ensures they will be part of the next frontier of exciting new therapies that simultaneously improve the accuracy of plaque diagnosis and more effectively reduce atherosclerosis with limited side effects.<br />Competing Interests: Conflict of interest: none declared.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Details

Language :
English
ISSN :
1755-3245
Volume :
120
Issue :
8
Database :
MEDLINE
Journal :
Cardiovascular research
Publication Type :
Academic Journal
Accession number :
38696700
Full Text :
https://doi.org/10.1093/cvr/cvae099